Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Sarepta Therapeutics, Inc./ 10-K

Annual Report · 10-K

Sarepta Therapeutics, Inc.

SRPTNASDAQEQUITYCurrent

Annual Report

Filed Feb 28, 2023Accepted Feb 28, 2023, 4:04 PM ESTCIK 873303Accession 0000950170-23-005062
View company →Permanent SEC source ↗
Share

Company context

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.

Current securities

SRPTNASDAQ · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive AgreementSep 23, 2026
  2. 13F-HR filingAug 14, 2026
  3. SCHEDULE 13G/A filingAug 13, 2026
  4. Results of Operations and Financial ConditionAug 5, 2026
  5. 10-Q filingAug 5, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗